(CAMBRIDGE, UK AND TORONTO, CANADA) September 06, 2018 – Breakthrough innovation specialist Cambridge Consultants has partnered with Exact Imaging, makers of the ExactVu™ micro-ultrasound platform, as the two companies work to improve the way prostate cancer is visualized and detected. Cambridge Consultants is applying deep learning to high-resolution micro-ultrasound imaging to identify potential suspicious regions of tissue and inform urologists who may want to consider this additional data in their biopsy protocol. Early results show real promise.

Prostate cancer is the second most common cause of cancer death in men in both the USA and the UK. There is an urgent need for improved accuracy in the detection and diagnosis of aggressive prostate cancers. The current standard-of-care ultrasound, which guides prostatic needle biopsies that help to diagnose prostate cancer, yields a 30% false negative rate as the resolution of the ultrasound systems is insufficient to differentiate suspicious regions. As such, the prostate biopsies are usually delivered in a systematic, “blind” pattern [1].

The ExactVu™ micro-ultrasound platform is a significant new imaging tool to allow urologists to harness “micro” ultrasound’s near microscopic resolution in order to visualize suspicious regions and actually target their biopsies to those regions. Operating at 29 MHz, the micro-ultrasound provides a 300% improvement in resolution over conventional ultrasound.

Cambridge Consultants aims to harness higher resolution micro-ultrasound images from the ExactVu™ platform, in combination with decades of medical technology expertise and cutting-edge machine learning techniques, to provide new information to urologists to help them to improve their targeting of prostate biopsies. In recent years Cambridge Consultants has been at the forefront of advances in machine learning and deep learning, applying this transformative technology to a wide range of industries and disciplines.

With their AI tools able to interrogate the full ultrasound data set correlated to pathology, the analysis should deliver improved accuracy and better characterization of suspicious regions. The machine learning approach being applied is faster and less computationally intensive than traditional statistical approaches and may ultimately form the backbone of a commercially-viable software application. Early results from proof of concept testing show significant promise, even with relatively limited data sets.

Shweta Gupta, Head of Urology and Women’s Health at Cambridge Consultants commented: “The need for effective management of prostate cancer is as pressing as ever. We are proud to have the opportunity to try and improve the detection pathway and excited by the opportunity to apply deep learning to this significant clinical problem.”

The current work on prostate cancer is the latest output from Cambridge Consultants’ Digital Greenhouse [2]  – a unique experimental environment where data scientists and engineers explore and develop cutting edge machine learning and deep learning techniques. Recent work has focused on applying deep learning in areas where massive datasets are unavailable - in this case data was available on hundreds of patients - aiming to ensure that deep learning is potent beyond the huge online datasets that have powered advances to date.

[1] https://www.ncbi.nlm.nih.gov/pubmed/23452046#
[2] http://digitalgreenhouse.ai/

Notes to editors

About Cambridge Consultants
Cambridge Consultants develops breakthrough products, services and intellectual property, and provides business consultancy in technology-critical issues for clients worldwide. For more than 60 years, the company has been helping its clients turn business opportunities into commercial successes, whether they are launching first-to-market products, entering new markets or expanding existing markets through the introduction of new technologies. With a team of more than 800 team members, including engineers, scientists, mathematicians and designers, in offices in Cambridge (UK), Boston (USA), Tokyo (Japan) and Singapore, Cambridge Consultants offers solutions across a diverse range of industries including medical technology, industrial and consumer products, digital health, energy and wireless communications.

Visit us: www.cambridgeconsultants.com

About Capgemini Invent
As the digital innovation, design and transformation brand of the Capgemini Group, Capgemini Invent enables CxOs to envision and shape the future of their businesses. Located in nearly 40 studios and more than 60 offices around the world, it comprises a 10,000+ strong team of strategists, data scientists, product and experience designers, brand experts and technologists who develop new digital services, products, experiences and business models for sustainable growth.

Capgemini Invent is an integral part of Capgemini, a global leader in partnering with companies to transform and manage their business by harnessing the power of technology. The Group is guided everyday by its purpose of unleashing human energy through technology for an inclusive and sustainable future. It is a responsible and diverse organization of over 325,000 team members in more than 50 countries. With its strong 55-year heritage and deep industry expertise, Capgemini is trusted by its clients to address the entire breadth of their business needs, from strategy and design to operations, fueled by the fast evolving and innovative world of cloud, data, AI, connectivity, software, digital engineering and platforms. The Group reported in 2021 global revenues of €18 billion.

Get The Future You Want

Visit us at www.capgemini.com/invent

 

Exact Imaging (www.exactimaging.com) is the world’s leader in high-resolution micro-ultrasound systems enabling real-time imaging and guided biopsies in the urological market for prostate cancer. Exact Imaging’s ExactVu™ micro-ultrasound platform operates at 29 MHz and enables a whole new level of resolution with the benefits of ease of use, affordability, and being an extension of the current urological workflow. Using the Exact Imaging platform, urologists are able to visualize areas of interest in the prostate and specifically target biopsies at those areas. For the minority of cases where MRI might assist (i.e., prior negative biopsies), the FusionVu™ micro-US/MRI fusion application operates on the ExactVu micro-ultrasound platform and facilitates MRI fusion-based targeting. The ExactVu micro-ultrasound system has received regulatory approval in the European Union (CE Mark), the United States (FDA 510(k)) and Canada (Health Canada medical device license).

PRESS CONTACTS

WE Communications

Matt
Urquhart